Redeye reinforces its positive stance on Guard following a transfer of coverage and a review of the case. We regard the shares as fundamentally undervalued and believe the market fails to recognise the company’s progress in clinical advancements. Our base case of SEK 3.0 per share implies +100% upside potential.